IMMUNOHISTOCHEMICAL EXPRESSION OF HER2/neu IN GASTRIC AND GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
European Journal of Molecular & Clinical Medicine,
2022, Volume 9, Issue 6, Pages 1131-1152
AbstractINTRODUCTION: Gastric cancer is one of the prominent reasons of cancer death worldwide andin India. The majority of individuals are diagnosed at a late stage. Various chemotherapy regimens have improved overall survival slightly. The HER2 protein, which is overexpressed in many stomach tumours, is a novel therapeutic target. Trastuzumab, a monoclonal antibody that targets HER2, has been found to enhance overall survival in advanced gastric cancer.AIMS AND OBJECTIVES:(1) To examine the frequency of expression of HER2 in gastric and GEJadenocarcinoma.(2) To find its correlation with clinicopathological parameters. MATERIALS AND METHODS: The study included 80 instances of stomach adenocarcinomas (44 biopsies and 16 gastrectomies) detected in the department of Pathology at Mallareddy Medical College for Women in Hyderabad over the previous two years (November 2019 to November 2021). A study of the slides confirmed the diagnosis, and IHC with anti- HER2 antibodies was performed using the Dako Real Envision Detection system, and scoring was done using the Hoffmann et al scoring system.RESULTS: The 80 cases were mostly male (60%) and averaged 65 years old. Males (30.6%) had HER2 positive. GEJ had 45.45% HER2 positive. Intestinal type 18 (30.5%) has HER2. The diffuse type was HER2-negative. Moderately differentiated (37.5%) tumours were HER2 positive (23.0 percent ). Poorly differentiated tumours were HER2-negative..CONCLUSION: HER2 positivity was found in 26.7% of cases. A significant correlation of HER2 positivity was found with male gender, intestinal type and moderatelydifferentiated carcinomas.
- Article View: 72
- PDF Download: 59